A U.S. Supreme Court ruling in April makes it easier for the makers of generic drugs to bring successful counterclaims against brand-name drug companies that try to thwart them from bringing products to market. In a 9-to-0 decision, the court reversed a ruling by the U.S. Court of Appeals for the Federal Circuit, finding that a district court judge was right to conclude in 2009 that Danish pharma giant Novo Nordisk A/S must correct information it provided to the Food and Drug Administration about its diabetes drug Prandin. The decision should allow Caraco Pharmaceutical Laboratories Ltd., a subsidiary of Sun Pharmaceutical Industries Limited, to market a generic version.
More significantly, the ruling expands the scope of the so-called counterclaim provision of the Hatch-Waxman Act, which lets generic companies challenge the accuracy of patent information that branded drug companies supply to the FDA. In doing so, the ruling sheds light on a murky provision of Hatch-Waxman. Under the law, the FDA won’t approve generic drugs for uses covered by patents owned by branded drug makers.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
